Article Text
Abstract
INTRODUCTION
Inherited genetic disorders account for about 5% of all medical consultations. The importance of a genetic contribution to a widening spectrum of disorders is becoming evident in neurology, indeed in all facets of medicine. Genetic factors may contribute to the development of disease, influence its course and severity, prognosis and response to therapy. Therefore, as our knowledge of the human genome expands, efforts are being made to identify genetic predispositions and influences to improve identification of risk, target pharmacotherapy, design gene therapy, and to provide more accurate assessment of prognosis. Recognition of risk should facilitate timely screening and early or presymptomatic treatment when available; and even in the absence of accepted treatment strategies this may still encourage appropriate lifestyle measures to reduce risk.
Better assessment of genetic risk is therefore an essential part of modern clinical assessment in all patients. A comprehensive family history is the first step and
Statistics from Altmetric.com
Read the full text or download the PDF:
Other content recommended for you
- A cluster-randomised, parallel group, controlled intervention study of genetic prostate cancer risk assessment and use of PSA tests in general practice—the ProCaRis study: study protocol
- Parental mosaicism detection and preimplantation genetic testing in families with multiple transmissions of de novo mutations
- Considering complexity in the genetic evaluation of dilated cardiomyopathy
- Gene therapy for neuromuscular disorders: prospects and ethics
- Genetic testing in motor neurone disease
- Genetic risk assessment can identify women with high venous thromboembolism risk contributing to precision medicine and personalised care
- Gene therapy: targeting the myocardium
- Genetic discrimination and mental illness: a case report
- Gene doping: an overview and current implications for athletes
- Protocol for Health Risk Information Technology-Assisted Genetic Evaluation (HeRITAGE): a randomised controlled trial of digital genetic cancer risk assessment in a diverse underserved gynaecology clinic